Perrigo (PRGO) Cash & Equivalents (2012 - 2026)
Perrigo (PRGO) posted quarterly Cash & Equivalents of $357.2 million for Q1 2026, down 12.86% year-over-year from $409.9 million in Q1 2025, and down 32.81% quarter-over-quarter from $531.6 million in Q4 2025.
Perrigo (PRGO) Cash & Equivalents (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Cash & Equivalents for 15 consecutive years, with $357.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 12.86% year-over-year to $357.2 million; the TTM figure through Mar 2026 stood at $357.2 million (down 12.86% YoY), while the FY2025 annual figure was $531.6 million, down 4.87% from the prior year.
- Cash & Equivalents fell to $357.2 million in Q1 2026 per PRGO's latest filing, from $531.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $2.0 billion in Q2 2022 and bottomed at $357.2 million in Q1 2026.
- Historically, Cash & Equivalents has averaged $669.8 million across 5 years, with a median of $553.0 million in 2023.
- On a YoY basis, Cash & Equivalents climbed as much as 317.39% in 2022 and fell as far as 77.45% in 2022.
- Perrigo's Cash & Equivalents stood at $600.7 million in 2022, then climbed by 25.07% to $751.3 million in 2023, then slipped by 25.62% to $558.8 million in 2024, then decreased by 4.87% to $531.6 million in 2025, then plunged by 32.81% to $357.2 million in 2026.
- Business Quant data shows PRGO's Cash & Equivalents at $357.2 million in Q1 2026, $531.6 million in Q4 2025, and $432.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | 399.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 399.70 Mn |
| Mar 28, 2026 | 357.20 Mn |
| Dec 31, 2025 | 531.60 Mn |
| Sep 27, 2025 | 432.10 Mn |
| Jun 28, 2025 | 454.20 Mn |
| Mar 29, 2025 | 409.90 Mn |
| Dec 31, 2024 | 558.80 Mn |
| Sep 28, 2024 | 1.46 Bn |
| Jun 29, 2024 | 542.80 Mn |
| Mar 30, 2024 | 658.50 Mn |
| Dec 31, 2023 | 751.30 Mn |
| Sep 30, 2023 | 598.30 Mn |
| Jul 1, 2023 | 555.20 Mn |
| Apr 1, 2023 | 553.00 Mn |
| Dec 31, 2022 | 600.70 Mn |
| Oct 1, 2022 | 468.70 Mn |
| Jul 2, 2022 | 485.30 Mn |
| Apr 2, 2022 | 1.97 Bn |
| Dec 31, 2021 | 1.86 Bn |
| Oct 2, 2021 | 2.08 Bn |